New Delhi, Jul 31 (PTI) Sun Pharmaceutical Industries on Thursday reported a 20 per cent year-on-year decline in consolidated net profit to Rs 2,279 crore for the first quarter ended June 30, 2025.
The Mumbai-based drug major posted a net profit of Rs 2,836 crore for the April-June quarter of the last financial year.
Adjusted net profit, excluding the exceptional items, for the first quarter stood at Rs 2,996 crore, up 6 per cent year-on-year.
Total income rose to 14,316 crore for the June quarter against Rs 13,185 crore in the year-ago period, Sun Pharma said in a regulatory filing.
Sun Pharma Chairman and Managing Director Dilip Shanghvi said the drug maker had a strong performance during the quarter, where the overall growth reflects steady progress across all its markets.
"India continues to show strong momentum, contributing meaningfully to our performance. The US launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata," he added.
Leqselvi augments the company's portfolio in dermatology and adds a growth engine to the innovative medicines business, Shanghvi said.
The company said the formulation sales in India stood at Rs 4,721 crore, up by 14 per cent year-on-year.
India formulation sales accounted for 34 per cent of total consolidated sales during the quarter, it added.
Formulation sales in the US were at USD 473 million, accounting for over 29 per cent of total consolidated sales, it said.
Global Innovative Medicines sales stood at USD 311 million for the June quarter, up 17 per cent as compared with the same period last year.
Emerging market formulations sales were at USD 298 million in the quarter under review, up by 5 per cent as compared to a year ago, Sun Pharma said.
For Q1FY26, external sales of API (active pharmaceutical ingredients) were at Rs 540 crore, up by 9 per cent year-on-year.
Shares of the company ended 1.69 per cent down at Rs 1,705.55 apiece on the BSE.